Anzeige
Mehr »
Login
Donnerstag, 23.05.2024 Börsentäglich über 12.000 News von 688 internationalen Medien
InnoCan Pharma: Jetzt in die Doppel-Chance investieren?!
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A2JF20 | ISIN: US09075P1057 | Ticker-Symbol: BX2
Tradegate
23.05.24
15:54 Uhr
1,800 Euro
-0,016
-0,88 %
Branche
Biotechnologie
Aktienmarkt
Sonstige
1-Jahres-Chart
BIOXCEL THERAPEUTICS INC Chart 1 Jahr
5-Tage-Chart
BIOXCEL THERAPEUTICS INC 5-Tage-Chart
RealtimeGeldBriefZeit
1,7761,79817:23
1,7771,79817:10

Aktuelle News zur BIOXCEL THERAPEUTICS Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
DiBioXcel Therapeutics Announces Oral and Poster Presentations at the 2024 American Society of Clinical Psychopharmacology (ASCP) Annual Meeting5
09.05.Earnings call: BioXcel Therapeutics reports progress in Q1 202427
09.05.BioXcel Therapeutics, Inc. - 10-Q, Quarterly Report6
09.05.BioXcel Therapeutics GAAP EPS of -$0.87 misses by $0.12, revenue of $0.58M misses by $0.05M13
09.05.BioXcel Therapeutics, Inc. - 8-K, Current Report5
08.05.BioXcel Therapeutics Q1 2024 Earnings Preview22
24.04.BioXcel Therapeutics Announces Late-Breaking Abstract on Preliminary Findings from Phase 2 Investigator-Sponsored Trial of BXCL701 and KEYTRUDA in Metastatic Pancreatic Ductal Adenocarcinoma (PDAC) Selected for Presentation at 2024 ASCO Annual Meeting184Poster presentation scheduled for June 1, 2024, 1:30-4:30 PM CT /2:30-5:30 PM ET Trial being led by Georgetown University's Lombardi Comprehensive Cancer Center NEW HAVEN, Conn., April 24, 2024 (GLOBE...
► Artikel lesen
22.04.BioXcel Therapeutics, Inc. - 8-K, Current Report8
10.04.BioXcel Therapeutics Announces TRANQUILITY In-Care Pivotal Phase 3 Trial Plan With BXCL501 for Agitation Associated With Alzheimer's Dementia205Company plans to initiate trial following recent meeting with FDA No FDA-approved therapies for acute treatment of AAD are currently available NEW HAVEN, Conn., April 10, 2024 (GLOBE NEWSWIRE) --...
► Artikel lesen
10.04.BioXcel Therapeutics, Inc. - 8-K, Current Report11
03.04.BioXcel Therapeutics, Inc. - S-8, Securities to be offered to employees in employee benefit plans11
25.03.BioXcel Therapeutics, Inc. - 8-K, Current Report7
25.03.BioXcel launches $25M direct offering of stock and warrants11
25.03.BioXcel Therapeutics secures $25 million in direct offering8
25.03.BioXcel Therapeutics Announces $25 Million Registered Direct Offering17
22.03.BioXcel Therapeutics, Inc. - 10-K, Annual Report11
15.03.BioXcel Therapeutics secures European patent for dementia treatment19
15.03.BioXcel Therapeutics Announces European Patent Office's Grant of Patent for Method of Treating Agitation in Dementia Using Sublingual Dexmedetomidine6
12.03.BioXcel Therapeutics Inc reports results for the quarter ended in December - Earnings Summary16
12.03.BioXcel Therapeutics rises on narrower Q4 loss12
Seite:  Weiter >>
67 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
5,2,11